A Study of SRSD384 in Overweight or Obese Participants

Summary

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).

Timeline

Start

2026-06

Primary completion

2027-10

Completion

2027-10

Drugs

Indications